Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Apr 4;147(4):1206-1215.
doi: 10.1093/brain/awad409.

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome

Collaborators, Affiliations
Randomized Controlled Trial

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome

Helmut Butzkueven et al. Brain. .

Abstract

Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive. The effects of vitamin D supplementation to prevent multiple sclerosis is unknown. We aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that the therapeutic effect is dose-dependent, and that all doses are safe and well tolerated. We conducted a double-blind trial in Australia and New Zealand. Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks. Between 2013 and 2021, we enrolled 204 participants. Brain MRI scans were performed at baseline, 24 and 48 weeks. The main study outcome was conversion to clinically definite multiple sclerosis based on the 2010 McDonald criteria defined as either a clinical relapse or new brain MRI T2 lesion development. We included 199 cases in the intention-to-treat analysis based on assigned dose. Of these, 116 converted to multiple sclerosis by 48 weeks (58%). Compared to placebo, the hazard ratios (95% confidence interval) for conversion were 1000 IU 0.87 (0.50, 1.50); 5000 IU 1.37 (0.82, 2.29); and 10 000 IU 1.28 (0.76, 2.14). In an adjusted model including age, sex, latitude, study centre and baseline symptom number, clinically isolated syndrome onset site, presence of infratentorial lesions and use of steroids, the hazard ratios (versus placebo) were 1000 IU 0.80 (0.45, 1.44); 5000 IU 1.36 (0.78, 2.38); and 10 000 IU 1.07 (0.62, 1.85). Vitamin D3 supplementation was safe and well tolerated. We did not demonstrate reduction in multiple sclerosis disease activity by vitamin D3 supplementation after a high-risk clinically isolated syndrome.

Keywords: clinical trial; multiple sclerosis; vitamin D.

PubMed Disclaimer

Conflict of interest statement

H.B.'s Institution receives compensation for H.B. serving on scientific advisory boards and trial steering committees for Biogen, Merck, Roche, and Novartis. His institutions receive research support from NHMRC, MRFF, MS Australia, Trish MS Foundation, Pennycook Foundation, Roche, Merck, Novartis, Sanofi, Alexion, and Biogen. H.B. has received conference travel support from Novartis. S.A.B. has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Schering, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Genzyme, has received speakers’ honoraria from Biogen-Idec and Genzyme, is an investigator in clinical trials sponsored by Biogen Idec, Novartis and Genzyme, and was the recipient of an unencumbered research grant from Biogen-Idec. T.K., J.L.S, M.B., W.C., P.M., R.M. or his institution have received remuneration for his speaking engagements, advisory board memberships, research and travel from Biogen, Merck, Genzyme, Bayer, Roche, Teva, Novartis, CSL, BMS, MedDay and NHMRC. T.K. served on scientific advisory boards for MS International Federation and World Health Organisation, BMS, Roche, Janssen, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Roche, Sanofi-Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck. A.v.d.W. served on advisory boards for Novartis, Biogen, Merck and Roche and NervGen. She received unrestricted research grants from Novartis, Biogen, Merck and Roche. She is currently a co-Principal investigator on a co-sponsored observational study with Roche, evaluating a Roche-developed smartphone app, Floodlight-MS. She has received speaker's honoraria and travel support from Novartis, Roche, Biogen and Merck. She serves as the Chief operating Officer of the MSBase Foundation (not for profit). F.B. Steering committee or Data Safety Monitoring Board member for Biogen, Merck, ATRI/ACTC and Prothena. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. B.V.T. or his institute have received honoraria for speaking from Novartis and Merck he has served on advisory boards for Merck and Novartis, he serves on the Australian National Blood Authority Scientific Working Group.

Figures

Figure 1
Figure 1
PREVANZ study, flow chart of participants. AE = adverse event; IMP = Investigational Medicinal Product; ITT = intention to treat; IU = international units.
Figure 2
Figure 2
Baseline and within study achieved serum 25(OH)D levels. (A) Distribution of baseline serum 25(OH)D3 levels (nmol/l). (B) Mean serum 25(OH)D3 (nmol/l) levels by treatment group/dose and week (with 95% confidence intervals, CIs). (C) Mean serum 25(OH)D3 concentrations over the 48-week study period post baseline for all trial arms.
Figure 3
Figure 3
Outcomes for all participants by assigned treatment. MRI conversions plotted above clinical conversions and right-censored (non-converted) participants, and then plotted in order of failure time. Grey lines show time on study without conversion. Short light grey lines ending in a black dot show clinical conversions. Dark grey lines show intervals between MRI scans during which radiological conversion took place. IU = international units.
Figure 4
Figure 4
Centre-specific risk of conversion per day on study. Centre-specific risk of conversion per day on study, limited to those centres with more than four participants recruited. The symbol sizes (areas) are proportional to the number of participants accrued.

Comment in

References

    1. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: A review. JAMA. 2021;325:765–779. - PubMed
    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391:1622–1636. - PubMed
    1. Zarghami A, Li Y, Claflin SB, van der Mei I, Taylor BV. Role of environmental factors in multiple sclerosis. Expert Rev Neurother. 2021;21:1389–1408. - PubMed
    1. International Multiple Sclerosis Genetics Consortium . Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365:eaav7188. - PMC - PubMed
    1. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25–36. - PubMed

Publication types

Associated data

Grants and funding